Allosteric Modulation of G Protein-coupled Receptors

Allosteric Modulation of G Protein-Coupled Receptors reviews fundamental information on G protein-coupled receptors (GPCRs) and allosteric modulation, presenting original research in the area and collectively providing a comprehensive description of key issues in GPCR allosteric modulation. The book provides background on core concepts of molecular pharmacology while also introducing the most important advances and studies in the area. It also discusses key methodologies. This is an essential book for researchers and advanced students engaged in pharmacology, toxicology and pharmaceutical sciences training and research.

Many of the GPCR-targeted drugs released in the past decade have specifically worked via allosteric mechanisms. Unlike direct orthosteric-acting compounds that occupy a similar receptor site to that of endogenous ligands, allosteric modulators alter GPCR-dependent signaling at a site apart from the endogenous ligand. Recent methodological and analytical advances have greatly improved our ability to understand the signaling mechanisms of GPCRs. We now know that allostery is a common regulatory mechanism for all GPCRs and not – as we once believed – unique to a few receptor subfamilies.

• Introduces background on core concepts of molecular pharmacology, including statistical analyses, non-linear regression, complex models and GPCR-dependent signal transduction as they relate to allosteric modulation
• Discusses critical advances and landmark studies, including discoveries in the area of GPCR allosteric modulation, which are reviewed for their importance in positive and negative regulation, protein-protein interactions, and small molecule drug discovery
• Includes key methodologies used to study allosteric modulation at the in silico, in vitro, and in vivo levels of drug discovery and characterization

Robert Laprairie is the GlaxoSmithKline-Canadian Institutes of Health Research chair in Drug Discovery and Development in the College of Pharmacy and Nutrition at the University of Saskatchewan. He currently serves as the President and Director of Education and Trainee Initiatives for the Canadian Consortium for the Investigation of Cannabinoids (CCIC). His teaching responsibilities include basic molecular pharmacology and neuroscience in the undergraduate and graduate Pharmacy programs. He is also involved in committee work with the Canadian Institutes of Health Research and the Animal Research Ethics Board of the University of Saskatchewan. Dr. Laprairie has published more than 50 articles on pharmacology with a focus on the endocannabinoid system and allosteric modulators.